Opendata, web and dolomites

AptaCheck

Bioelectronic lab-on-a-chip for point-of-care detection of infectious agents

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AptaCheck project word cloud

Explore the words cloud of the AptaCheck project. It provides you a very rough idea of what is the project "AptaCheck" about.

adequately    automated    flu    portability    2024    elisa    fast    aptamer    mover    3bn    approvals    easily    scanner    beats    reader    downstream    electronic    600    antibody    15    outbreaks    clinical    preventing    8m    simplicity    platform    74    diagnostics    observation    financing    equipped    jobs    clinically    later    advantage    communication    pcr    house    special    display    microbiological    diagnosis    supply    wireless    enter    handling    detection    cumulative    identifications    secure    care    consolidated    poc    transfer    departments    markets    skills    isolated    optimisation    infectious    biochips    overcome    manufacturing    direct    infections    immediately    eventual    disposable    action    industry    revenues    scalable    industrial    human    chip    approved    groundbreaking    market    chain    patients    obligatory    drug    cutting    hospitals    samples    clinics    wifi    accuracy    point    2020    minutes    edge    time    qr    aptachek    first    semi    lab    aptacheck    parallel    versatile    gastroenteritis    accurate    drawbacks    complete    biosensor    data    linked    instability    quality    pathogens    strategic    lower    detecting    turnover   

Project "AptaCheck" data sheet

The following table provides information about the project.

Coordinator
SOLSTEN DIAGNOSTICS AS 

Organization address
address: HEDEAGER 40
city: AARHUS N
postcode: 8200
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website https://solsten-diag.com
 Total cost 2˙254˙187 €
 EC max contribution 1˙577˙931 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-08-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SOLSTEN DIAGNOSTICS AS DK (AARHUS N) coordinator 1˙577˙931.00

Map

 Project objective

AptaCheck is a groundbreaking platform for detecting infections pathogens in human samples: the first aptamer-based biosensor platform with lab-quality accuracy, allowing a fast, clinically accurate diagnosis. AptaCheck will overcome the drawbacks of the antibody based point-of-care (POC) devices (lower accuracy and instability). Aptacheck is equipped with a hand-held reader, which comprises a display for direct observation, a QR scanner for identifications, and WiFi for data transfer. AptaCheck beats the state of the art: - Cost: The disposable chip will cost the end user €10 - Time: Turnover-time is less than 15 minutes including sample handling - Accuracy: AptaCheck will be more reliable than ELISA and comparable to PCR - Simplicity: No special equipment or skills are needed - Portability: The hand-held reader and biochips can be used at the point of care - Communication: AptaCheck will be linked to electronic lab systems via wireless communication - Action: Patients can adequately be treated; Infectious patients can immediately be isolated preventing eventual outbreaks - Versatile: AptaCheck can easily be adapted to detection of new pathogens. We consolidated our first-mover advantage in in-house, robust, semi-automated, cutting-edge, up-scalable industrial production process for the biochips. AptaChek will be approved and deployed in clinical microbiological departments in hospitals. Later it will be deployed at clinics, drug manufacturing industry, etc. With Phase II financing, AptaCheck will enter a €3.3bn market for gastroenteritis diagnostics in 2020, and produce €74.8m in cumulative revenues for FLU and 600 new jobs in FLU and the supply chain by 2024. FLU seeks funding to complete the system optimisation for pre-clinical testing and for the obligatory clinical approvals. In parallel to this, we will secure a key strategic downstream distribution partner, and investigate new markets and applications in the diagnostics sector for the AptaCheck platform.

 Deliverables

List of deliverables.
Portfolio of communication material Other 2020-02-18 15:41:04

Take a look to the deliverables list in detail:  detailed list of AptaCheck deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "APTACHECK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "APTACHECK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

SUPPLEPRINT (2018)

Super Productive Line Printing Inkjet

Read More  

Volumizer (2018)

A natural, non-surgical, and safe facial filler which treats the root cause of facial ageing.

Read More  

HIL PT System (2017)

Revolutionary, cost effective, spatially efficient, proton therapy system for cancer treatment.

Read More